{
    "title": "109_hr3950",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Responsibility in Drug Advertising \nAct of 2005''.\n\nSEC. 2. DIRECT-TO-CONSUMER DRUG ADVERTISING.\n\n    The Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) is \namended--\n            (1) in section 301, by adding at the end the following:\n    ``(hh) The conduct of direct-to-consumer advertising of a drug in \nviolation of section 506D.''; and\n            (2) in chapter V, by inserting after section 506C the \n        following:\n\n``SEC. 506D. DIRECT-TO-CONSUMER DRUG ADVERTISING.\n\n    ``(a) Prohibitions.--\n            ``(1) First three years.--\n                    ``(A) In general.--Subject to subparagraph (B), no \n                person shall conduct direct-to-consumer advertising of \n                a drug for which an application is submitted under \n                section 505(b) before the end of the 3-year period \n                beginning on the date of the approval of such \n                application.\n                    ``(B) Waiver.--The Secretary may waive the \n                application of subparagraph (A) to a drug during the \n                third year of the 3-year period described in such \n                subparagraph if--\n                            ``(i) the sponsor of the drug submits an \n                        application to the Secretary pursuant to \n                        subparagraph (C); and\n                            ``(ii) the Secretary, after considering the \n                        application and any accompanying materials, \n                        determines that direct-to-consumer advertising \n                        of the drug would have an affirmative value to \n                        public health.\n                    ``(C) Application for waiver.--To seek a waiver \n                under subparagraph (B), the sponsor of a drug shall \n                submit an application to the Secretary at such time, in \n                such manner, and containing such information as the \n                Secretary may require.\n            ``(2) Subsequent years.--The Secretary may prohibit direct-\n        to-consumer advertising of a drug during the period beginning \n        at the end of the 3-year period described in paragraph (1)(A) \n        if the Secretary determines that the drug has significant \n        adverse health effects based on post-approval studies, risk-\n        benefit analyses, adverse event reports, the scientific \n        literature, any clinical or observational studies, or any other \n        appropriate resource.\n    ``(b) Regulations.--Not later than 1 year after the date of the \nenactment of this section, the Secretary shall revise the regulations \npromulgated under this Act governing drug advertisements to the extent \nnecessary to implement this section.\n    ``(c) Rule of Construction.--This section shall not be construed to \ndiminish the authority of the Secretary to prohibit or regulate direct-\nto-consumer advertising of drugs under other provisions of law.\n    ``(d) Effective Date.--This section applies only with respect to a \ndrug for which an application submitted under section 505(b) is \napproved on or after the date that is 1 year before the date of the \nenactment of this section.''.\n\nSEC. 3. PROMINENT DISPLAY OF INFORMATION IN ADVERTISING ON SIDE \n              EFFECTS, CONTRAINDICATIONS, AND EFFECTIVENESS.\n\n    (a) Requirement.--Paragraph (3) of section 502(n) of the Federal \nFood, Drug, and Cosmetic Act (21 U.S.C. 352(n)) is amended--\n            (1) by redesignating subparagraphs (A) and (B) as clauses \n        (i) and (ii); and\n            (2) by striking ``such other information'' and all that \n        follows through ``which shall be issued by'' and inserting \n        ``such other information in brief summary relating to side \n        effects, contraindications, and effectiveness as shall be \n        required in regulations which (A) shall require such \n        information to be prominently displayed in terms of font size \n        and location and (B) shall be issued by''.\n    (b) Effective Date.--The amendment made by this section applies \nwith respect to any advertisement or other descriptive printed matter \nthat is issued or caused to be issued on or after the date that is 90 \ndays after the enactment of this Act. Not later than such date, the \nSecretary shall revise any regulations promulgated pursuant to \nsubsection (n) of section 503 of the Federal Food, Drug, and Cosmetic \nAct (21 U.S.C. 352) to the extent necessary to implement this section.\n\nSEC. 4. CIVIL PENALTY.\n\n    Section 303 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n333) is amended by adding at the end the following:\n    ``(g) Drug Advertising and Promotion.--\n            ``(1) Civil penalty.--\n                    ``(A) In general.--Any manufacturer, packer, or \n                distributor of a drug who violates section 505(n), \n                section 506D, or any other requirement of this Act \n                relating to the advertising or promotion of the drug \n                shall be subject to a civil penalty in an amount not to \n                exceed--\n                            ``(i) in the case of the first such \n                        violation by the manufacturer, packer, or \n                        distributor relating to the drug, $250,000; and\n                            ``(ii) in the case of each subsequent \n                        violation by the manufacturer, packer, or \n                        distributor relating to the drug, an amount \n                        that is twice the amount of the maximum civil \n                        penalty applicable under this subparagraph to \n                        the previous violation.\n                    ``(B) Procedure.--Paragraphs (3) through (5) of \n                subsection (f) shall apply with respect to a civil \n                penalty under subparagraph (A) to the same extent and \n                in the same manner as those paragraphs apply with \n                respect to a civil penalty under paragraph (1) or (2) \n                of subsection (f).\n            ``(2) Distribution of materials.--If the Secretary finds \n        that a person committed a violation described in paragraph \n        (1)(A), the Secretary may order the person to distribute \n        materials in the same markets in which the violative \n        advertisement or promotional material was distributed in a \n        manner designed to notify the public and the medical community \n        of the violation and to provide corrective information.\n            ``(3) Separate offense.--For purposes of imposing a civil \n        penalty under this subsection, each violation described in \n        paragraph (1)(A), including each distribution of a direct-to-\n        consumer advertisement in violation of section 506A, shall \n        constitute a separate offense.\n            ``(4) Relation to other penalties.--A civil penalty under \n        paragraph (1) and an order under paragraph (2) shall be in \n        addition to any other penalty applicable under this Act or \n        other law to the violation involved.''.\n\nSEC. 5. ORDER REQUIRING POSTMARKET CHANGE IN LABELING.\n\n    The Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) is \namended--\n            (1) in section 502, by adding at the end the following:\n    ``(x) If it is a drug and its labeling fails to comply with an \norder issued pursuant to section 506E, or the manufacturer of the drug \nfails to provide notification to physicians as required by the \nSecretary pursuant to such section.''; and\n            (2) by inserting after section 506D, as added by section 2, \n        the following:\n\n``SEC. 506E. POSTMARKET CHANGE IN LABELING.\n\n    ``(a) In General.--In the case of any drug for which an approval of \nan application submitted under section 505(b) or (j) is in effect, the \nSecretary may require by order that information, including specific \nwording, be included in the labeling of a drug on the basis that such \ninformation is necessary to ensure the safe and effective use of the \ndrug.\n    ``(b) Notification.--If the Secretary issues an order described in \nsubsection (a), the Secretary may require the manufacturer of the drug \ninvolved to notify the public and the medical community of the labeling \nchange.''.\n\nSEC. 6. PUBLIC EDUCATION CAMPAIGN ON RISKS OF CERTAIN DRUGS.\n\n    The Secretary of Health and Human Services shall conduct an \neducation campaign to increase public awareness of risks that, for some \npatients, may outweigh the benefits of using a particular drug, whether \nsuch risks are known at the time of the approval of the drug or become \nknown after the approval of the drug.\n\nSEC. 7. ADDITIONAL FUNDING FOR REGULATION OF DIRECT-TO-CONSUMER DRUG \n              ADVERTISING.\n\n    There are authorized to be appropriated to the Food and Drug \nAdministration $2,500,000 for each of fiscal years 2007 and 2008 for \nthe purpose of regulating direct-to-consumer drug advertisements, \nincluding by carrying out the amendments made by section 2. The \nauthorization of appropriations in the preceding sentence is in \naddition to any other authorization of appropriations for such purpose."
}